Viet Nam Pharmaceutical Corporation - Joint Stock Co
UUPCOM:DVN17,100.00
VND
-100.00
(-0.58%)
ISIN
VN000000DVN7
Return %
Stock
S&P 500
1Y
-16.99
14.20
3Y
-8.56
81.12
5Y
-28.75
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Han Xuan Dinh
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- Ha Noi Vietnam
- IPO Date
- May 19, 2017
- Website
- vinapharm.com.vn
- Similar Companies
- Business
- Viet Nam Pharmaceutical Corporation - Joint Stock Company (Vinapharm) is a Vietnam-based healthcare enterprise primarily engaged in the manufacture, import, export, trading, and distribution of pharmaceuticals, active pharmaceutical ingredients, and medical supplies. Founded in 1971 and headquartered in Hanoi, Vietnam, the corporation operates through an integrated network of subsidiaries, member companies, and joint-venture entities nationwide. The company provides a comprehensive portfolio of products and services, including: ethical and over-the-counter finished pharmaceuticals across therapeutic categories such as anti-infectives, cardiovascular treatments, analgesics, antipyretics, respiratory medications, gastrointestinal remedies, and metabolic agents; traditional herbal medicines, nutraceuticals, and dietary supplements; active pharmaceutical ingredients (APIs), chemical intermediates, excipients, and primary packaging materials; medical devices, surgical equipment, diagnostic consumables, and laboratory supplies; and commercial services encompassing Good Storage Practice (GSP) and Good Distribution Practice (GDP) compliant cold-chain warehousing, nationwide logistics, regulatory filing, and drug registration agency services. Vinapharm serves state-owned and private hospitals, healthcare centers, medical clinics, commercial distributors, and retail pharmacy chains throughout Vietnam, while exporting selected product lines across Southeast Asia. In recent operational developments, the corporation has advanced state capital restructuring initiatives in coordination with the State Capital Investment Corporation (SCIC), refined equity participation across major domestic manufacturing subsidiaries and multinational joint ventures such as Sanofi-Synthelabo Vietnam, and expanded strategic collaborations with international pharmaceutical manufacturers to facilitate technology transfer and upgrade domestic production facilities to EU-GMP and PIC/S standards, while simultaneously modernizing its digital supply chain and pharmaceutical logistics infrastructure.